U.S. flag

An official website of the United States government

NM_003560.4(PLA2G6):c.2215G>C (p.Asp739His) AND Infantile neuroaxonal dystrophy

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Nov 24, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000793778.8

Allele description [Variation Report for NM_003560.4(PLA2G6):c.2215G>C (p.Asp739His)]

NM_003560.4(PLA2G6):c.2215G>C (p.Asp739His)

Gene:
PLA2G6:phospholipase A2 group VI [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q13.1
Genomic location:
Preferred name:
NM_003560.4(PLA2G6):c.2215G>C (p.Asp739His)
Other names:
NM_003560.4(PLA2G6):c.2215G>C; p.Asp739His
HGVS:
  • NC_000022.11:g.38112565C>G
  • NG_007094.3:g.107214G>C
  • NG_033059.2:g.3105G>C
  • NM_001004426.3:c.2053G>C
  • NM_001199562.3:c.2053G>C
  • NM_001349864.2:c.2215G>C
  • NM_001349865.2:c.2053G>C
  • NM_001349866.2:c.2053G>C
  • NM_001349867.2:c.1681G>C
  • NM_001349868.2:c.1537G>C
  • NM_001349869.2:c.1519G>C
  • NM_003560.4:c.2215G>CMANE SELECT
  • NP_001004426.1:p.Asp685His
  • NP_001186491.1:p.Asp685His
  • NP_001336793.1:p.Asp739His
  • NP_001336794.1:p.Asp685His
  • NP_001336795.1:p.Asp685His
  • NP_001336796.1:p.Asp561His
  • NP_001336797.1:p.Asp513His
  • NP_001336798.1:p.Asp507His
  • NP_003551.2:p.Asp739His
  • LRG_1015t1:c.2215G>C
  • LRG_1015:g.107214G>C
  • LRG_1015p1:p.Asp739His
  • NC_000022.10:g.38508572C>G
  • NG_007094.2:g.98126G>C
  • NM_003560.2:c.2215G>C
Protein change:
D507H
Links:
dbSNP: rs587784349
NCBI 1000 Genomes Browser:
rs587784349
Molecular consequence:
  • NM_001004426.3:c.2053G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001199562.3:c.2053G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349864.2:c.2215G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349865.2:c.2053G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349866.2:c.2053G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349867.2:c.1681G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349868.2:c.1537G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349869.2:c.1519G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_003560.4:c.2215G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Infantile neuroaxonal dystrophy (NBIA2A)
Synonyms:
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; Seitelberger disease; Infantile neuroaxonal dystrophy 1
Identifiers:
MONDO: MONDO:0024457; MedGen: C0270724; Orphanet: 35069; OMIM: 256600

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000933150Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Nov 24, 2023)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.

Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA, Levinson B, Woods CG, et al.

Nat Genet. 2006 Jul;38(7):752-4. Epub 2006 Jun 18. Erratum in: Nat Genet. 2006 Aug;38(8):957.

PubMed [citation]
PMID:
16783378
PMCID:
PMC2117328

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000933150.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 739 of the PLA2G6 protein (p.Asp739His). This variant is present in population databases (rs587784349, gnomAD 0.006%). This missense change has been observed in individual(s) with clinical features of PLA2G6-related conditions (PMID: 16783378; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 159761). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PLA2G6 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024